These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 15598950)

  • 1. Extended rituximab therapy in Waldenström's macroglobulinemia.
    Treon SP; Emmanouilides C; Kimby E; Kelliher A; Preffer F; Branagan AR; Anderson KC; Frankel SR;
    Ann Oncol; 2005 Jan; 16(1):132-8. PubMed ID: 15598950
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression of complement inhibitors CD46, CD55, and CD59 on tumor cells does not predict clinical outcome after rituximab treatment in follicular non-Hodgkin lymphoma.
    Weng WK; Levy R
    Blood; 2001 Sep; 98(5):1352-7. PubMed ID: 11520782
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Paradoxical increases in serum IgM and viscosity levels following rituximab in Waldenstrom's macroglobulinemia.
    Treon SP; Branagan AR; Hunter Z; Santos D; Tournhilac O; Anderson KC
    Ann Oncol; 2004 Oct; 15(10):1481-3. PubMed ID: 15367407
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CD20-directed antibody-mediated immunotherapy induces responses and facilitates hematologic recovery in patients with Waldenstrom's macroglobulinemia.
    Treon SP; Agus TB; Link B; Rodrigues G; Molina A; Lacy MQ; Fisher DC; Emmanouilides C; Richards AI; Clark B; Lucas MS; Schlossman R; Schenkein D; Lin B; Kimby E; Anderson KC; Byrd JC
    J Immunother; 2001; 24(3):272-9. PubMed ID: 11394506
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of Waldenström's macroglobulinemia with rituximab.
    Dimopoulos MA; Zervas C; Zomas A; Kiamouris C; Viniou NA; Grigoraki V; Karkantaris C; Mitsouli C; Gika D; Christakis J; Anagnostopoulos N
    J Clin Oncol; 2002 May; 20(9):2327-33. PubMed ID: 11981004
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Extended rituximab therapy for previously untreated patients with Waldenström's macroglobulinemia.
    Dimopoulos MA; Zervas C; Zomas A; Hamilos G; Gika D; Efstathiou E; Panayiotidis P; Vervessou E; Anagnostopoulos N; Christakis J
    Clin Lymphoma; 2002 Dec; 3(3):163-6. PubMed ID: 12521393
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CHOP plus rituximab therapy in Waldenstrom's macroglobulinemia.
    Treon SP; Hunter Z; Barnagan AR
    Clin Lymphoma; 2005 Mar; 5(4):273-7. PubMed ID: 15794864
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Soluble CD27 is a faithful marker of disease burden and is unaffected by the rituximab-induced IgM flare, as well as by plasmapheresis, in patients with Waldenström's macroglobulinemia.
    Ciccarelli BT; Yang G; Hatjiharissi E; Ioakimidis L; Patterson CJ; Manning RJ; Xu L; Liu X; Tseng H; Gong P; Sun J; Zhou Y; Treon SP
    Clin Lymphoma Myeloma; 2009 Mar; 9(1):56-8. PubMed ID: 19362974
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CD20 levels determine the in vitro susceptibility to rituximab and complement of B-cell chronic lymphocytic leukemia: further regulation by CD55 and CD59.
    Golay J; Lazzari M; Facchinetti V; Bernasconi S; Borleri G; Barbui T; Rambaldi A; Introna M
    Blood; 2001 Dec; 98(12):3383-9. PubMed ID: 11719378
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of complement regulatory proteins: CD46, CD55, and CD59 and response to rituximab in patients with CD20+ non-Hodgkin's lymphoma.
    Dzietczenia J; Wróbel T; Mazur G; Poreba R; Jaźwiec B; Kuliczkowski K
    Med Oncol; 2010 Sep; 27(3):743-6. PubMed ID: 19662541
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rituximab (anti-CD20) therapy of B-cell lymphomas: direct complement killing is superior to cellular effector mechanisms.
    Harjunpää A; Junnikkala S; Meri S
    Scand J Immunol; 2000 Jun; 51(6):634-41. PubMed ID: 10849376
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pentostatin/cyclophosphamide with or without rituximab: an effective regimen for patients with Waldenstrom's macroglobulinemia/lymphoplasmacytic lymphoma.
    Hensel M; Villalobos M; Kornacker M; Krasniqi F; Ho AD
    Clin Lymphoma Myeloma; 2005 Sep; 6(2):131-5. PubMed ID: 16231851
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lenalidomide and rituximab in Waldenstrom's macroglobulinemia.
    Treon SP; Soumerai JD; Branagan AR; Hunter ZR; Patterson CJ; Ioakimidis L; Chu L; Musto P; Baron AD; Nunnink JC; Kash JJ; Terjanian TO; Hyman PM; Nawfel EL; Sharon DJ; Munshi NC; Anderson KC
    Clin Cancer Res; 2009 Jan; 15(1):355-60. PubMed ID: 19118065
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rituximab therapy in Waldenstrom's macroglobulinemia: preliminary evidence of clinical activity.
    Byrd JC; White CA; Link B; Lucas MS; Velasquez WS; Rosenberg J; Grillo-López AJ
    Ann Oncol; 1999 Dec; 10(12):1525-7. PubMed ID: 10643548
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Once-weekly ofatumumab in untreated or relapsed Waldenström's macroglobulinaemia: an open-label, single-arm, phase 2 study.
    Furman RR; Eradat HA; DiRienzo CG; Hofmeister CC; Hayman SR; Leonard JP; Coleman M; Advani R; Chanan-Khan A; Switzky J; Liao QM; Shah D; Jewell RC; Lisby S; Lin TS
    Lancet Haematol; 2017 Jan; 4(1):e24-e34. PubMed ID: 27914971
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical value of minor responses after 4 doses of rituximab in Waldenström macroglobulinaemia: a follow-up of the Eastern Cooperative Oncology Group E3A98 trial.
    Gertz MA; Abonour R; Heffner LT; Greipp PR; Uno H; Rajkumar SV
    Br J Haematol; 2009 Dec; 147(5):677-80. PubMed ID: 19751237
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Myelopathy from Waldenström's macroglobulinemia: improvement after Rituximab therapy.
    Liberato B; Riethmuller A; Comenzo RL; Lis E; Raizer JJ
    J Neurooncol; 2003 Jun; 63(2):207-11. PubMed ID: 12825826
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Effective treatment with rituximab in two patients with Waldenström macroglobulinemia].
    Yoshimi A; Arai S; Iijima K; Iki S; Usuki K; Urabe A
    Rinsho Ketsueki; 2005 Oct; 46(10):1109-13. PubMed ID: 16440772
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Thalidomide and rituximab in Waldenstrom macroglobulinemia.
    Treon SP; Soumerai JD; Branagan AR; Hunter ZR; Patterson CJ; Ioakimidis L; Briccetti FM; Pasmantier M; Zimbler H; Cooper RB; Moore M; Hill J; Rauch A; Garbo L; Chu L; Chua C; Nantel SH; Lovett DR; Boedeker H; Sonneborn H; Howard J; Musto P; Ciccarelli BT; Hatjiharissi E; Anderson KC
    Blood; 2008 Dec; 112(12):4452-7. PubMed ID: 18713945
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Complement-binding proteins are strongly expressed by human preimplantation blastocysts and cumulus cells as well as gametes.
    Taylor CT; Johnson PM
    Mol Hum Reprod; 1996 Jan; 2(1):52-9. PubMed ID: 9238658
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.